Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition.
Erlmeier F, Klümper N, Landgraf L, Strissel PL, Strick R, Sikic D, Taubert H, Wach S, Geppert CI, Bahlinger V, Breyer J, Ritter M, Bolenz C, Roghmann F, Erben P, Schwamborn K, Wirtz RM, Horn T, Wullich B, Hölzel M, Hartmann A, Gschwend JE, Weichert W, Eckstein M. Erlmeier F, et al. Among authors: geppert ci. Eur Urol. 2023 Feb;83(2):133-142. doi: 10.1016/j.eururo.2022.10.020. Epub 2022 Nov 10. Eur Urol. 2023. PMID: 36372626 Free article.
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy.
Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C, Wullweber A, Lange F, Erben P, Stoehr R, Bertz S, Geppert CI, Fuhrich N, Taubert H, Wach S, Breyer J, Otto W, Burger M, Bolenz C, Keck B, Wullich B, Hartmann A, Sikic D; BRIDGE Consortium e.V., Mannheim, Germany. Eckstein M, et al. Among authors: geppert ci. J Immunother Cancer. 2020 May;8(1):e000162. doi: 10.1136/jitc-2019-000162. J Immunother Cancer. 2020. PMID: 32448798 Free PMC article.
Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes.
Eckstein M, Matek C, Wagner P, Erber R, Büttner-Herold M, Wild PJ, Taubert H, Wach S, Sikic D, Wullich B, Geppert CI, Compérat EM, Lopez-Beltran A, Montironi R, Cheng L, van der Kwast T, Colecchia M, van Rhijn BWG, Amin MB, Netto GJ, Lehmann J, Stöckle M, Junker K, Hartmann A, Bertz S. Eckstein M, et al. Among authors: geppert ci. Eur Urol Oncol. 2024 Feb;7(1):128-138. doi: 10.1016/j.euo.2023.07.011. Epub 2023 Aug 8. Eur Urol Oncol. 2024. PMID: 37562993 Free article.
Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)].
Eckstein M, Matek C, Wagner P, Erber R, Büttner-Herold M, Wild PJ, Taubert H, Wach S, Sikic D, Wullich B, Geppert CI, Compérat EM, Lopez-Beltran A, Montironi R, Cheng L, van der Kwast T, Colecchia M, van Rhijn BWG, Amin MB, Netto GJ, Lehmann J, Stöckle M, Junker K, Hartmann A, Bertz S. Eckstein M, et al. Among authors: geppert ci. Eur Urol Oncol. 2023 Dec;6(6):641. doi: 10.1016/j.euo.2023.09.023. Epub 2023 Oct 7. Eur Urol Oncol. 2023. PMID: 37813744 Free article. No abstract available.
Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
Bahlinger V, Branz A, Strissel PL, Strick R, Lange F, Geppert CI, Klümper N, Hölzel M, Wach S, Taubert H, Sikic D, Wullich B, Angeloni M, Ferrazzi F, Diehl L, Kovalenko M, Elboudwarej E, Jürgensmeier JM, Hartmann A, Eckstein M. Bahlinger V, et al. Among authors: geppert ci. Histopathology. 2024 Apr;84(5):863-876. doi: 10.1111/his.15130. Epub 2024 Jan 9. Histopathology. 2024. PMID: 38196202
A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing.
Angeloni M, van Doeveren T, Lindner S, Volland P, Schmelmer J, Foersch S, Matek C, Stoehr R, Geppert CI, Heers H, Wach S, Taubert H, Sikic D, Wullich B, van Leenders GJ, Zaburdaev V, Eckstein M, Hartmann A, Boormans JL, Ferrazzi F, Bahlinger V. Angeloni M, et al. Among authors: geppert ci. J Pathol Clin Res. 2024 Mar;10(2):e12369. doi: 10.1002/2056-4538.12369. J Pathol Clin Res. 2024. PMID: 38504364 Free PMC article.
96 results